Performance of A Point-of-care Fluorescence Immunoassay Test to measure anti Severe Acute Respiratory Syndrome Corona Virus 2 Spike, Receptor Binding Domain Antibody Level

Author:

Tiara Marita Restie,Djauhari Hofiya,Rachman Febi Ramdhani,Rettob Antonius Christianus,Utami Darmastuti,Pulungan Fahda Cintia Suci,Purwanta Heru,Wisaksana Rudi,Alisjahbana Bachti,Indrati Agnes Rengga

Abstract

AbstractQuantitative determination of anti-SARSCoV2-S-RBD is necessary for the evaluation of vaccination effectiveness. Surrogate viral neutralization test (SVNT) is approved for measuring anti-SARSCoV2-S-RBD, but a point-of-care platform is needed to simplify anti-SARS-CoV-2-S-RBD measurement. We aimed to evaluate the performance of a rapid fluorescent immunoassay-based kit, FastBio-RBDtm, compared to SVNT. During April–September 2021, we enrolled two groups of subjects; convalescent subject and subject without COVID-19 history. Subjects were tested for anti-SARS-CoV2-S-RBD antibody using FastBio-RBDtmand GenScript-cPASStmSVNT. We measured the correlation coefficient and conducted ROC analysis to determine the best cut-off value of anti-SARSCoV2-S-RBD against SVNT percent inhibition levels of 30% and 60%. We included 109 subjects. Anti-SARS-CoV-2-S-RBD strongly correlated to SVNT %-inhibition with R value = 0,866 (p < 0,0001). ROC analysis showed that anti-SARS-CoV-2-S-RBD of 6,71 AU/mL had 95,7% sensitivity and 87,5% specificity to detect percentage inhibition of 30%. Anti-SARS-CoV-2-S-RBD of 59,76 AU/mL had a sensitivity of 88,1% and specificity of 97,0% to detect percentage inhibition of 60%. FastBio-RBDtmcan determine the presence and level of anti-SARS-CoV-2-S-RBD with good sensitivity and specificity. It has the potential to be deployed in health facilities with limited resources.

Publisher

Cold Spring Harbor Laboratory

Reference23 articles.

1. Organization, W.H. WHO Director-General’s Opening Remarks at the Media Briefing on Covid-19. Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-1911-march-2020. (accessed on

2. Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021–January 2022

3. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis

4. Factors That Influence the Immune Response to Vaccination

5. Evaluation of antibody response after COVID‐19 vaccination of healthcare workers

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3